Welcome to our dedicated page for Fulcrum Therapeutics SEC filings (Ticker: FULC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Fulcrum Therapeutics, Inc. filings document the regulatory record of a clinical-stage biopharmaceutical company focused on small-molecule therapies for genetically defined rare diseases and rare hematological disorders. Form 8-K reports cover operating results, financial condition, Regulation FD corporate presentations, clinical updates for pociredir in sickle cell disease, and material agreements, including license arrangements tied to development programs.
Proxy materials disclose board and governance matters, executive compensation, equity awards, shareholder voting items, and related ownership information. The filing record also documents capital-structure items such as common stock and inducement equity plans alongside public-company disclosures tied to drug development programs and collaboration agreements.
Fulcrum Therapeutics director Katina Dorton received a new stock option award covering 32,000 shares of Common Stock. The option carries an exercise price of $3.66 per share and expires on June 29, 2036. It was granted at no upfront cost and is scheduled to vest in full on the first anniversary of the June 30, 2026 grant date or earlier, immediately before the first annual stockholder meeting after the grant date, subject to continued service. Following this grant, Dorton holds 32,000 stock options directly from this award.
Fulcrum Therapeutics director Robert J. Gould received a stock option grant for 32,000 shares of common stock. The option has an exercise price of $3.66 per share and expires on June 29, 2036. It was granted as compensation, not through an open-market transaction.
According to the terms, all 32,000 shares are scheduled to vest on the first anniversary of the June 30, 2026 grant date or, if earlier, immediately before the first annual meeting of stockholders after that date, as long as Gould continues to serve the company. Following this grant, his reported option holdings from this filing total 32,000 shares.
Fulcrum Therapeutics director Kate Haviland received a new stock option grant. She was awarded options covering 32,000 shares of Fulcrum Therapeutics common stock at an exercise price of $3.6600 per share.
The option was granted as of June 30, 2026 and is scheduled to vest in full on the first anniversary of the grant date or, if earlier, immediately before the first annual meeting of stockholders after the grant date, assuming continued service. Following this grant, she holds options for 32,000 shares directly.
Fulcrum Therapeutics director Rachel K. King received a grant of stock options covering 32,000 shares of common stock. These options give her the right to buy shares at an exercise price of $3.66 per share, aligning part of her compensation with the company’s future performance.
The option grant is scheduled to vest in full on the first anniversary of the June 30, 2026 grant date, or earlier immediately before the first annual stockholder meeting after that date, as long as she continues in service. After this grant, she holds options for 32,000 underlying shares that expire on June 29, 2036. This is a compensation-related award rather than an open-market purchase or sale.
Fulcrum Therapeutics, Inc. director James A. Geraghty received a grant of stock options covering 32,000 shares of common stock. The options have an exercise price of $3.66 per share and expire on June 29, 2036. According to the grant terms, all 32,000 options are scheduled to vest on the first anniversary of the June 30, 2026 grant date, or earlier immediately before the first annual stockholder meeting after that date, subject to his continued service.
Fulcrum Therapeutics director Colin Hill received a stock option grant covering 32,000 shares of Common Stock. The option has an exercise price of $3.66 per share and was granted as a compensation award, not as an open-market purchase or sale.
The option was granted on June 30, 2026 and is scheduled to vest in full on the first anniversary of the grant date or, if earlier, immediately before the first annual meeting of stockholders after the grant date, subject to continued service. Following this grant, Hill holds options for 32,000 shares directly, with an expiration date of June 29, 2036.
Fulcrum Therapeutics, Inc. director Alan Ezekowitz received a stock option grant covering 32,000 shares of common stock. The option has an exercise price of $3.66 per share and expires on June 29, 2036.
According to the terms, the option is scheduled to vest in full on the first anniversary of the June 30, 2026 grant date or, if earlier, immediately before the first annual stockholder meeting after the grant date, as long as service continues. Following this grant, his reported derivative holdings for this option total 32,000 shares.
Fulcrum Therapeutics director Alan Ezekowitz reported an open-market sale of common stock. He sold 18,000 shares of Fulcrum Therapeutics, Inc. at a weighted average price of $3.6452 per share, executed as multiple trades within a disclosed price range.
The transactions were made under a pre-arranged Rule 10b5-1 trading plan adopted by the reporting person on March 27, 2026. Following this sale, Ezekowitz directly holds 10,927 shares of Fulcrum Therapeutics common stock.
Fulcrum Therapeutics reports large passive holdings by EcoR1 and affiliated parties. EcoR1 Capital, LLC and Oleg Nodelman each report beneficial ownership of 6,000,000 shares (listed as 9.0% of common stock), and EcoR1 Capital Fund Qualified, L.P. reports 5,614,199 shares (8.4%), with percentages calculated using 66,633,321 shares outstanding as of April 20, 2026. The filing states shared voting and dispositive power for the reported holdings and includes a joint-filing agreement; the reporting persons disclaim group status and certain beneficial ownership beyond pecuniary interests.